 |
Prospector
Profile
3-31-002
|
| |
| Kosan Biosciences, Inc. |
NAICS |
541710 |
| 3832 Bay Center Place,
Hayward, CA 94545 |
Description |
Biotechnology |
| (510) 732-8400 |
Employees |
91 |
|
Revenue |
(mil) |
22.7100 |
| |
Income |
(mil) |
-28.6600 |
| |
Assets |
(mil) |
77.8700 |
| |
Liability |
(mil) |
18.3100 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Miscellaneous
|
| |
|
Event:
Kosan Biosciences, Inc., will reduce its workforce by approximately 37% to focus resources on supporting advancement of its lead clinical programs, tanespimycin in multiple myeloma and in metastatic breast cancer, and epothilone KOS-1584 in non-small lung cancer. The restructuring will primarily affect the Company's research and administrative functions. As a result of the restructuring, most research programs will be placed on hold. The Company may seek to partner these assets with companies looking for early-stage programs. Kosan Biosciences, Inc., reported a net loss of $28,658,000 on total revenues of $22,707,000 for the year ended December 31, 2007, as compared with a net loss of $29,469,000 on total revenues of $13,506,000. The Company also had a net loss of $29,637,000 on total revenues of $13,410,000 in 2005. As of December 31, 2008, the Company's balance sheet showed total assets of $77,867,000, total liabilities of $18,307,000, and total stockholders' equity of $59,560,000.
|
| |
|
Intellectual Property:
The Company's intellectual property consists of patents, copyrights, trademarks, trade secrets and know-how. Its ability to compete effectively depends on the ability to obtain patents and trademarks for its technologies and products, maintain trade secrets, operate without infringing the rights of others and prevent others from infringing proprietary rights. As of December 31, 2007, the Company owned or exclusively licensed approximately 143 patents and 79 patent applications in the U.S. and approximately 80 foreign patents and 265 foreign patent applications. It also relies on trade secrets to protect technology where patent protection is deemed inappropriate or unobtainable. It protects proprietary technology and processes, in part, by confidentiality agreements with employees, consultants, collaborators and certain contractors. [SEC Filing 10-K 03-17-08]
|
| |
|
Description:
Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing
various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is
in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II
clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer.
|
| |
|
Officers:
Gary S. Titus (CFO); Peter Licari (VP of Manufacturing); Pieter B.M.W.M. Timmermans (SVP);
Helen S. Kim (Pres., CEO)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock Symbol: KOSN: NasdaqGM; 42,592,302 common stock outstanding as of Feb. 29, 2008.
|
| |
| |
| |
| return to main page |
|
|
